Myeloid Marker Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-19143R |
| Product Name | Myeloid Marker Polyclonal Antibody |
| Applications |
WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Specificity | This antibody's immunogen sequence has 91% homology (10/11 residues) with the Rat MYADM protein and is predicted to work with Rat samples |
| Reactivity | Human |
| Predicted Reactivity | Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human MYADM |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 91663 |
| Swiss Prot | Q96S97 |
| Subcellular location | Cell membrane |
| Synonyms | MYADM; MYADM_HUMAN; myeloid associated differentiation marker; Myeloid upregulated protein; Myeloid-associated differentiation marker; Protein SB135. |
| Background | Myeloid-associated differentiation marker (MYADM) is a member of the MAL family with the unique features of having eight transmembrane regions and a ubiquitous pattern of expression and of being found localized at the plasma membrane. MYADM has been found to be associated with the differentiation of hematopoietic cells or acute promyelocytic leukemia cells. MYADM could serve as a new marker for hematopoietic differentiation and is a target for diagnostic, prognostic and/or therapeutic interventions. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |